April 8, 2019 10:51 AM EDT
R&D

Unit­ed kills its PhI­II PAH drug af­ter it fails Ty­va­so com­bo study

John Carroll

Editor & Founder

Just a few weeks af­ter San­doz pushed out a gener­ic ver­sion of Unit­ed Ther­a­peu­tics’ PAH drug Re­mod­ulin, Unit­ed was forced to con­cede an­oth­er set­back for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times